What are CD47 antibody drugs?

CD47 antibody drugs are pharmacologic agents that share a common mechanism (typically targeting CD47). 0 are currently marketed, with 6 more in clinical development.

CD47 antibody

0 marketed 3 in Phase 3 2 in Phase 2 1 in Phase 1

This page covers all CD47 antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD47.

Targets

CD47

Phase 3 pipeline (3)

TBI-1301 · Takara Bio Inc. · Oncology
TBI-1301 is a monoclonal antibody targeting CD47.
HP-802-247 · Healthpoint · Oncology
HP-802-247 is a monoclonal antibody targeting CD47.
TAK-667 · Takeda · Oncology
TAK-667 is a CD47 antibody that works by blocking the interaction between CD47 and SIRPα on macrophages, thereby promoting phagocytosis of tumor cells.

Phase 2 pipeline (2)

BAT4406F Injection · Bio-Thera Solutions · Oncology
BAT4406F Injection is a monoclonal antibody targeting CD47.
Ag-D-CIK · Shenzhen Hornetcorn Bio-technology Company, LTD · Oncology
Ag-D-CIK is a monoclonal antibody that targets CD47.

Phase 1 pipeline (1)

AK112, Cadonilimab, nab-paclitaxel, gemcitabine · Akeso · Oncology
CD47 antibody